Ensuring Access to Clinical Trials (EACT) Act Passes Senate
On July 16, 2015, the Ensuring Access to Clinical Trials Act (EACT), S 139/HR 209, which will permanently remove a barrier to clinical trial participation for those with rare diseases was passed in the United States Senate by unanimous consent.
EACT makes permanent the Improving Access to Clinical Trials Act (IACT), which was enacted in 2010 and allows those with rare diseases to receive compensation up to $2,000 for participating in clinical trials without that compensation counting towards their income eligibility for vital health benefits including SSI and Medicaid.
The LGDA joined with the Cystic Fibrosis Foundation and many other rare disease advocates in writing to members of Congress encouraging them to support the EACT.
Work continues to advocate for the passage of the bill in the House of Representatives and ensure that the Ensuring Access to Clinical Trials Act becomes law prior to IACT’s expiration in October 2015.